We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+39.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$831M
AUM Growth
+$203M
Cap. Flow
-$333M
Cap. Flow %
-40.1%
Top 10 Hldgs %
41.06%
Holding
181
New
59
Increased
25
Reduced
46
Closed
41

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$11.9M
2
AKRO
Akero Therapeutics
AKRO
+$9.31M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$9.18M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$6.77M
5
IMVT icon
Immunovant
IMVT
+$6.73M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$11.5M
2
INSM icon
Insmed
INSM
+$7.55M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$6.95M
4
BHVN icon
Biohaven
BHVN
+$6.68M
5
BMEA icon
Biomea Fusion
BMEA
+$6.06M

Sector Composition

Rank Sector Weight
1 Healthcare 31.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
76
PUT
DELISTED
Nuvalent
NUVL
$2.4M 0.29%
+523
New +$23.2K
VYGR icon
77
Voyager Therapeutics
VYGR
$183M
$2.37M 0.29%
305,857
+5,857
+2% +$53.5K
IFRX icon
78
InflaRx
IFRX
$250M
$2.05M 0.25%
+688,604
New +$2.62M
MRSN
79
DELISTED
Mersana Therapeutics
MRSN
$2.01M 0.24%
63,191
+61,191
+3,060% +$2.91M
ALLK
80
DELISTED
Allakos
ALLK
$1.79M 0.21%
787,056
+14,964
+2% +$55.6K
ESPR
81
DELISTED
Esperion Therapeutics
ESPR
$1.7M 0.2%
1,737,636
+32,031
+2% +$46.3K
NUVB icon
82
Nuvation Bio
NUVB
$2.2B
$1.64M 0.2%
+1,222,852
New +$2.04M
BDTX icon
83
Black Diamond Therapeutics
BDTX
$96.8M
$1.59M 0.19%
555,572
+10,469
+2% +$38.6K
APLS
84
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$1.57M 0.19%
412
-132,588
-100% -$5.82M
BIVI icon
85
BioVie
BIVI
$11.5M
$1.56M 0.19%
4,573
+87
+2% +$34K
CBAY
86
DELISTED
Cymabay Therapeutics
CBAY
$1.56M 0.19%
+104,300
New +$1.38M
AEON icon
87
AEON Biopharma
AEON
$12.9M
$1.44M 0.17%
+3,583
New +$1.64M
MIST icon
88
Milestone Pharmaceuticals
MIST
$138M
$1.43M 0.17%
462,828
+2,412
+0.5% +$7.5K
SLRN
89
CALL
DELISTED
ACELYRIN
SLRN
$1.39M 0.17%
1,369
-98,631
-99% -$2.09M
CRSP icon
90
CRISPR Therapeutics
CRSP
$4.73B
$1.39M 0.17%
+30,546
New +$1.58M
KALV
91
DELISTED
KalVista Pharmaceuticals
KALV
$1.37M 0.17%
142,692
+2,692
+2% +$27.5K
IRON icon
92
CALL
Disc Medicine
IRON
$2.96B
$1.33M 0.16%
+284
New +$14.2K
CRBP icon
93
Corbus Pharmaceuticals
CRBP
$166M
$1.32M 0.16%
195,899
+3,639
+2% +$25.2K
ABOS icon
94
Acumen Pharmaceuticals
ABOS
$155M
$1.31M 0.16%
315,265
-339,680
-52% -$2.1M
CBAY
95
PUT
DELISTED
Cymabay Therapeutics
CBAY
$1.22M 0.15%
+816
New +$10.8K
VTGN icon
96
VistaGen Therapeutics
VTGN
$9.89M
$1.2M 0.14%
+229,100
New +$1.02M
TECX
97
Tectonic Therapeutic
TECX
$529M
$1.11M 0.13%
59,855
+48,676
+435% +$861K
QURE icon
98
uniQure
QURE
$3.03B
$1.06M 0.13%
+157,365
New +$1.42M
KZR
99
DELISTED
Kezar Life Sciences
KZR
$1.02M 0.12%
85,339
+1,179
+1% +$20.9K
TERN
100
CALL
DELISTED
Terns Pharmaceuticals
TERN
$1.01M 0.12%
2,000
-198,000
-99% -$1.26M
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Ikarian Capital held 181 positions worth $831M, up 32% from $628M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital withdrew a net $333M in Q3 2023, closing 41 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $11.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 44% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Rocket Pharmaceuticals worth $13.4M.

  • Ikarian Capital's largest Q3 2023 buy was Rocket Pharmaceuticals: 654,726 shares worth $13.4M.
  • Ikarian Capital added most to Crinetics Pharmaceuticals in Q3 2023, an estimated $6.55M increase.
  • Ikarian Capital's biggest Q3 2023 reduction was Insmed, cutting an estimated $7.55M.
  • Ikarian Capital fully exited Merck in Q3 2023, selling an estimated $11.5M.
  • Ikarian Capital's ten largest holdings make up 41% of its $831M portfolio in Q3 2023.
  • Ikarian Capital opened 59 new positions and closed 41 in Q3 2023.
  • Ikarian Capital's portfolio value rose 32% quarter-over-quarter to $831M.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.